Matching articles for "diltiazem"
Issue 1752 · April 13, 2026
Etripamil Nasal Spray (Cardamyst) for Paroxysmal Supraventricular Tachycardia

The FDA has approved Cardamyst (Milestone), a nasal spray formulation of the nondihydropyridine calcium channel blocker etripamil, for conversion of acute symptomatic episodes of paroxysmal supraventricular…

Med Lett Drugs Ther. 2026 Apr 13; 68(1752):59-61 doi:10.58347/tml.2026.1752b
The FDA has approved Cardamyst (Milestone), a nasal spray formulation of the nondihydropyridine calcium channel blocker etripamil, for conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Cardamyst is the first product containing etripamil to be approved in the US. It is being marketed as the only FDA-approved, self-administered, rapid-acting treatment option for acute episodes of PSVT.
Issue 1732 · July 7, 2025 Free
Addendum: Drugs for Open-Angle Glaucoma

Our recent article on glaucoma stated that systemic adverse effects of ophthalmic beta blockers include bradycardia. A reader suggested we should have also mentioned that they rarely cause heart block,…

Med Lett Drugs Ther. 2025 Jul 7; 67(1732):112 doi:10.58347/tml.2025.1732e
Our recent article on glaucoma stated that systemic adverse effects of ophthalmic beta blockers include bradycardia. A reader suggested we should have also mentioned that they rarely cause heart block, particularly in patients receiving other negative chronotropic drugs such as verapamil or diltiazem, and when that occurs, stopping the ophthalmic beta blocker may avoid insertion of a pacemaker.
Issue 1728 · May 12, 2025
Landiolol (Rapiblyk) for Short-Term Rate Control in Supraventricular Tachycardia

The FDA has approved the intravenously administered beta 1 -adrenergic blocker landiolol ( Rapiblyk – AOP) for short-term reduction of ventricular rate in adults with supraventricular tachycardia including…

Med Lett Drugs Ther. 2025 May 12; 67(1728):75-6 doi:10.58347/tml.2025.1728b
The FDA has approved the intravenously administered beta 1 -adrenergic blocker landiolol ( Rapiblyk – AOP) for short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter. Esmolol ( Brevibloc , and generics), another IV beta blocker, was approved earlier for the same indication.
Issue 1703 · May 27, 2024
Drugs for Hypertension

American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed…

Med Lett Drugs Ther. 2024 May 27; 66(1703):81-8 doi:10.58347/tml.2024.1703a
American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed here.
Issue 1693 · January 8, 2024
Treatment of Atrial Fibrillation

Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of…

Med Lett Drugs Ther. 2024 Jan 8; 66(1693):1-8 doi:10.58347/tml.2024.1693a
Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines on management of AF were updated recently.
Issue 1693 · January 8, 2024
Treatment of Atrial Fibrillation

Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of…

Med Lett Drugs Ther. 2024 Jan 8; 66(1693):1-8 doi:10.58347/tml.2024.1693a
Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines on management of AF were updated recently.
Issue 1652 · June 13, 2022
Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy

The FDA has approved mavacamten ( Camzyos – MyoKardia/BMS), a modulator of cardiac myosin, to improve functional capacity and symptoms in adults with New York Heart Association (NYHA) class II or III…

Med Lett Drugs Ther. 2022 Jun 13; 64(1652):89-91
The FDA has approved mavacamten ( Camzyos – MyoKardia/BMS), a modulator of cardiac myosin, to improve functional capacity and symptoms in adults with New York Heart Association (NYHA) class II or III obstructive hypertrophic cardiomyopathy (HCM) who have a baseline left ventricular ejection fraction (LVEF) ≥55%. Mavacamten is the first drug in its class to become available in the US.
Issue 1598 · May 18, 2020
Drugs for Hypertension

Drugs available for treatment of chronic hypertension and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.

Med Lett Drugs Ther. 2020 May 18; 62(1598):73-80
Drugs available for treatment of chronic hypertension and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.
Issue 1580 · September 9, 2019
Drugs for Atrial Fibrillation

Treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. US guidelines were recently updated.

Med Lett Drugs Ther. 2019 Sep 9; 61(1580):137-44
Treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. US guidelines were recently updated.
Issue 1516 · March 13, 2017
Drugs for Hypertension

in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.

Med Lett Drugs Ther. 2017 Mar 13; 59(1516):41-8
in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.
Issue 1446 · July 7, 2014
Treatment of Atrial Fibrillation

The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been published.

Med Lett Drugs Ther. 2014 Jul 7; 56(1446):53-8
The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been published.
Issue 141 · May 1, 2014
Drugs for Hypertension

Most recent guidelines recommend a BP goal of 140/90 mm Hg. For patients ≥60 years old without diabetes or chronic kidney disease, one guideline recommends 150/90 mm Hg both as the drug treatment initiation…

Treat Guidel Med Lett. 2014 May; 12(141):31-8
Most recent guidelines recommend a BP goal of 140/90 mm Hg. For patients ≥60 years old without diabetes or chronic kidney disease, one guideline recommends 150/90 mm Hg both as the drug treatment initiation threshold and treatment target; this higher target is controversial, except in patients ≥80 years old.
Issue 113 · January 1, 2012
Drugs for Hypertension

Drugs available in the US for treatment of chronic hypertension, with their dosages and adverse effects, are listed in the tables that begin on page 2. Combination products are listed on page 8. Drugs for…

Treat Guidel Med Lett. 2012 Jan; 10(113):1-10
Drugs available in the US for treatment of chronic hypertension, with their dosages and adverse effects, are listed in the tables that begin on page 2. Combination products are listed on page 8. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed previously.
Issue 1370 · August 8, 2011
New Simvastatin Dosing Recommendations

The FDA has announced changes in the labeling of simvastatin to reduce the risk of myopathy. These changes include limiting the use of the 80-mg maximum dose to patients who have been taking it for 12 months…

Med Lett Drugs Ther. 2011 Aug 8; 53(1370):61-2
The FDA has announced changes in the labeling of simvastatin to reduce the risk of myopathy. These changes include limiting the use of the 80-mg maximum dose to patients who have been taking it for 12 months or more without evidence of myopathy and new recommendations for use of simvastatin with other drugs. Simvastatin is available alone ( Zocor , and others) and in combination with ezetimibe (Vytorin) and with niacin (Simcor) .
Issue 1337 · May 3, 2010
Everolimus and Pazopanib: Two New Drugs for Renal Cell Cancer

Everolimus ( Afinitor – Novartis) and pazopanib ( Votrient – GlaxoSmithKline), two oral multikinase inhibitors, have been approved by the FDA for treatment of advanced renal cell carcinoma. Sunitinib…

Med Lett Drugs Ther. 2010 May 3; 52(1337):33-4
Everolimus ( Afinitor – Novartis) and pazopanib ( Votrient – GlaxoSmithKline), two oral multikinase inhibitors, have been approved by the FDA for treatment of advanced renal cell carcinoma. Sunitinib (Sutent) and sorafenib (Nexavar) , two other oral multikinase inhibitors, and temsirolimus (Torisel) , an IV multikinase inhibitor, were approved earlier for the same indication.
Issue 1322 · October 5, 2009
Dronedarone (Multaq) for Atrial Fibrillation

Dronedarone ( Multaq - Sanofi-Aventis) has been approved by the FDA for oral treatment of atrial fibrillation and flutter. Amiodarone (Cordarone, and others) is the most effective drug for this indication, but…

Med Lett Drugs Ther. 2009 Oct 5; 51(1322):78-80
Dronedarone ( Multaq - Sanofi-Aventis) has been approved by the FDA for oral treatment of atrial fibrillation and flutter. Amiodarone (Cordarone, and others) is the most effective drug for this indication, but has considerable toxicity.
Issue 77 · January 1, 2009
Drugs for Hypertension

Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs…

Treat Guidel Med Lett. 2009 Jan; 7(77):1-10
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed in Treatment Guidelines ( volume 1, page 19, December 2002 ) and in The Medical Letter ( volume 50, page 73, September 22, 2008 ).
Issue 1297 · October 20, 2008
Drug Interactions with Simvastatin

A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin ( Zocor , and others) and green tea. Since it became…

Med Lett Drugs Ther. 2008 Oct 20; 50(1297):83-4
A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin ( Zocor , and others) and green tea. Since it became available generically, simvastatin has surpassed atorvastatin ( Lipitor ) as the best selling statin. As such, it is probably the most common cause of statin-induced myopathy, which is often a result of drug interactions.
Issue 58 · June 1, 2007
Drugs for Cardiac Arrhythmias

The drugs of choice for treatment of common cardiac arrhythmias are listed in Tables 1 and 2. Some drugs are recommended for indications that have not been approved by the FDA.

Treat Guidel Med Lett. 2007 Jun; 5(58):51-8
The drugs of choice for treatment of common cardiac arrhythmias are listed in Tables 1 and 2. Some drugs are recommended for indications that have not been approved by the FDA.
Issue 34 · June 1, 2005
Drugs for Hypertension

Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs…

Treat Guidel Med Lett. 2005 Jun; 3(34):39-48
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs for treatment of hypertensive emergencies are not discussed here.
Issue 27 · November 1, 2004
Drugs for Cardiac Arrhythmias

The drugs of choice for treatment of common cardiac arrhythmias are listed in the table that begins on the next page; some drugs are recommended for indications for which they have not been approved by the US…

Treat Guidel Med Lett. 2004 Nov; 2(27):75-82
The drugs of choice for treatment of common cardiac arrhythmias are listed in the table that begins on the next page; some drugs are recommended for indications for which they have not been approved by the US FDA. The dosages and adverse effects of each drug are listed in the table that begins on page 80. Antiarrhythmic drugs may themselves cause arrhythmias, which can be fatal. Some of these drugs may increase rather than decrease mortality, especially in patients with structural heart disease.
Issue 1186 · July 5, 2004
Initial Therapy of Hypertension

The importance of adequate control of hypertension in preventing organ damage and death is well established, but the choice of drugs is still controversial. Three recent drug trials, one supporting initial…

Med Lett Drugs Ther. 2004 Jul 5; 46(1186):53-5
The importance of adequate control of hypertension in preventing organ damage and death is well established, but the choice of drugs is still controversial. Three recent drug trials, one supporting initial therapy with a diuretic, the second favoring an angiotensin converting enzyme (ACE) inhibitor, and the third showing equivalence between a calcium-channel blocker and an angiotensin-receptor blocker (ARB) have intensified the debate.
Issue 1176 · February 16, 2004
Drugs for Intermittent Claudication

Management of intermittent claudication, the most common symptom of peripheral arterial disease (PAD), involves both risk factor modification and symptomatic treatment (WR Hiatt, N Engl J Med 2001; 344:1608;…

Med Lett Drugs Ther. 2004 Feb 16; 46(1176):13-5
Management of intermittent claudication, the most common symptom of peripheral arterial disease (PAD), involves both risk factor modification and symptomatic treatment (WR Hiatt, N Engl J Med 2001; 344:1608; RM Schainfeld, J Am Board Fam Pract 2001; 14:443).
Issue 1173 · January 5, 2004
Drug Interactions with Grapefruit Juice

The ability of grapefruit juice to increase serum concentrations of drugs was first discovered during a study of the effect of ethanol on felodipine (Plendil) pharmacokinetics. Double-strength grapefruit juice…

Med Lett Drugs Ther. 2004 Jan 5; 46(1173):2-4
The ability of grapefruit juice to increase serum concentrations of drugs was first discovered during a study of the effect of ethanol on felodipine (Plendil) pharmacokinetics. Double-strength grapefruit juice used to disguise the taste of ethanol resulted in higher than expected serum concentrations of felodipine (DG Bailey et al, Clin Invest Med 1989; 12:357).
Issue 1158 · June 8, 2003
Drug Interactions

Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug…

Med Lett Drugs Ther. 2003 Jun 8; 45(1158):46-8
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.
Issue 6 · February 1, 2003
Drugs for Hypertension

Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs…

Treat Guidel Med Lett. 2003 Feb; 1(6):33-40
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs for treatment of hypertensive emergencies were discussed in Treatment Guidelines volume 1, issue 4, page 19, December 2002.
Issue 1141 · October 14, 2002
Generic drugs

When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent to the…

Med Lett Drugs Ther. 2002 Oct 14; 44(1141):89-90
When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent to the brand-name product?
Issue 1127 · April 1, 2002
Bosentan (Tracleer) for Pulmonary Arterial Hypertension

Bosentan ( Tracleer - Actelion), a non-peptide endothelin receptor antagonist, has been approved by the FDA for oral treatment of patients who have pulmonary arterial hypertension (PAH) with symptoms of…

Med Lett Drugs Ther. 2002 Apr 1; 44(1127):30-2
Bosentan ( Tracleer - Actelion), a non-peptide endothelin receptor antagonist, has been approved by the FDA for oral treatment of patients who have pulmonary arterial hypertension (PAH) with symptoms of dyspnea at rest or with minimal exertion.
Issue 1099 · March 5, 2001
Drugs for Hypertension

Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.

Med Lett Drugs Ther. 2001 Mar 5; 43(1099):17-22
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.
Issue 1071 · February 7, 2000
Sirolimus (Rapamune) for Transplant Rejection

Sirolimus, whlch is structurally related to tacrolimus, has been approved by the FDA for prevention of acute renal transplant rejection. The manufacturer recommends that sirolimus be taken with cyclosporine…

Med Lett Drugs Ther. 2000 Feb 7; 42(1071):13-4
Sirolimus, whlch is structurally related to tacrolimus, has been approved by the FDA for prevention of acute renal transplant rejection. The manufacturer recommends that sirolimus be taken with cyclosporine and corticosteroids.
Issue 1056 · July 2, 1999
Drug Interactions

Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new drugs.

Med Lett Drugs Ther. 1999 Jul 2; 41(1056):59-62
Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new drugs.
Issue 1052 · May 7, 1999
Cilostazol for Intermittent Claudication

Cilostazol, a phosphodiesterase III inhibitor that has been used in Japan since 1988, has been approved by the FDA for treatment on intermittent claudication due to occlusive peripheral arterial disease.

Med Lett Drugs Ther. 1999 May 7; 41(1052):44-6
Cilostazol, a phosphodiesterase III inhibitor that has been used in Japan since 1988, has been approved by the FDA for treatment on intermittent claudication due to occlusive peripheral arterial disease.
Issue 1048 · March 12, 1999
Drugs for Hypertension

Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.

Med Lett Drugs Ther. 1999 Mar 12; 41(1048):23-8
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.
Issue 1013 · November 7, 1997
Mibefradil--A New Calcium-Channel Blocker

Mibefradil dihydrochloride ( Posicor - Roche), a chemically distinct nondihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration (FDA) and is being heavily promoted as…

Med Lett Drugs Ther. 1997 Nov 7; 39(1013):103-5
Mibefradil dihydrochloride ( Posicor - Roche), a chemically distinct nondihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration (FDA) and is being heavily promoted as the first T-type calcium-channel blocker for treatment of hypertension and chronic stable angina.
Issue 994 · February 14, 1997
Safety of Calcium-Channel Blockers

Reports of increased mortality associated with calcium-channel blockers have caused concerns among patients taking these drugs and their physicians.

Med Lett Drugs Ther. 1997 Feb 14; 39(994):13-4
Reports of increased mortality associated with calcium-channel blockers have caused concerns among patients taking these drugs and their physicians.
Issue 968 · February 16, 1996
Nisoldipine-A New Calcium-Channel Blocker for Hypertension

Nisoldipine (Sular -Zeneca), a dihydropyridine calcium-channel blocker structurally similar to nifedipine, has been approved for marketing by the US Food and Drug Administration. It is available in an oral…

Med Lett Drugs Ther. 1996 Feb 16; 38(968):13-4
Nisoldipine (Sular -Zeneca), a dihydropyridine calcium-channel blocker structurally similar to nifedipine, has been approved for marketing by the US Food and Drug Administration. It is available in an oral extended-release formulation for treatment of hypertension.
Issue 955 · August 18, 1995
Grapefruit Juice Interactions With Drugs

In a study of the interaction between alcohol and the calcium-channel blocker felodipine ( Plendil ), the grapefruit juice vehicle for the alcohol appeared to increase felodipine plasma concentrations.…

Med Lett Drugs Ther. 1995 Aug 18; 37(955):73-4
In a study of the interaction between alcohol and the calcium-channel blocker felodipine ( Plendil ), the grapefruit juice vehicle for the alcohol appeared to increase felodipine plasma concentrations. Subsequent studies have found that grapefruit juice increases plasma concentrations of several calcium-channel blockers and of some other drugs as well (DG Bailey et al, Clin Pharmacokinet, 26:91, 1994).
Issue 937 · December 9, 1994
Drugs for Stable Angina Pectoris

Many nitrates, beta-blockers, and calcium-channel blockers have now been approved by the US Food and Drug Administration for treatment of stable angina pectoris. The table beginning on page 112 lists the…

Med Lett Drugs Ther. 1994 Dec 9; 36(937):111-4
Many nitrates, beta-blockers, and calcium-channel blockers have now been approved by the US Food and Drug Administration for treatment of stable angina pectoris. The table beginning on page 112 lists the individual drugs, their dosage, and their cost.
Issue 882 · October 30, 1992
Amlodipine - A New Calcium-Channel Blocker

Amlodipine (am loe' di peen) besylate ( Norvasc - Pfizer), a dihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration for once-daily oral treatment of hypertension,…

Med Lett Drugs Ther. 1992 Oct 30; 34(882):99-100
Amlodipine (am loe' di peen) besylate ( Norvasc - Pfizer), a dihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration for once-daily oral treatment of hypertension, chronic stable angina, and vasospastic (Prinzmetal's) angina.
Issue 859 · December 13, 1991
Felodipine - Calcium-Channel Blocker For Hypertension

Felodipine ( Plendil - Merck), an extended-release preparation of a dihydropyridine calcium-channel blocker was recently marketed in the USA for oral treatment of hypertension. An immediate-release formulation…

Med Lett Drugs Ther. 1991 Dec 13; 33(859):115-6
Felodipine ( Plendil - Merck), an extended-release preparation of a dihydropyridine calcium-channel blocker was recently marketed in the USA for oral treatment of hypertension. An immediate-release formulation is available in some other countries.
Issue 845 · May 31, 1991
Isradipine For Hypertension

Isradipine ( DynaCirc - Sandoz), a dihydropyridine calcium-channel blocker chemically related to nicardipine ( Cardene ) and nifedipine ( Procardia , and others), was recently approved by the US Food and Drug…

Med Lett Drugs Ther. 1991 May 31; 33(845):51-2
Isradipine ( DynaCirc - Sandoz), a dihydropyridine calcium-channel blocker chemically related to nicardipine ( Cardene ) and nifedipine ( Procardia , and others), was recently approved by the US Food and Drug Administration for oral treatment of hypertension.
Issue 845 · May 31, 1991
Bepridil for Angina Pectoris

Bepridil hydrochloride ( Vascor - McNeil Pharmaceutical/Wallace Laboratories), a calcium-channel blocking agent chemically unrelated to verapamil ( Calan , and others), nifedipine ( Procardia , and others), or…

Med Lett Drugs Ther. 1991 May 31; 33(845):53-4
Bepridil hydrochloride ( Vascor - McNeil Pharmaceutical/Wallace Laboratories), a calcium-channel blocking agent chemically unrelated to verapamil ( Calan , and others), nifedipine ( Procardia , and others), or other drugs in this class, was recently approved by the US Food and Drug Administration for oral treatment of chronic stable angina pectoris. Because of its potential adverse effects, the labeling recommends reserving the drug for patients who fail to respond optimally to or are intolerant of other antianginal agents.
Issue 791 · May 5, 1989
Nicardipine - A New Calcium-Entry Blocker

Nicardipine ( Cardene - Syntex), a dihydropyridine calcium-entry blocker structurally related to nifedipine ( Procardia ; Adalat), was recently approved by the US Food and Drug Administration for oral…

Med Lett Drugs Ther. 1989 May 5; 31(791):41-2
Nicardipine ( Cardene - Syntex), a dihydropyridine calcium-entry blocker structurally related to nifedipine ( Procardia ; Adalat), was recently approved by the US Food and Drug Administration for oral treatment of angina and hypertension. Advertisements for the drug claim that nicardipine is more vasoselective; than other calcium-channel blockers and does not depress myocardial contractility.